A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy

被引：3
|
作者：
Lee, Seo Young [1 ]
Kim, Min Hwan [1 ]
Jang, Mi [2 ]
Park, Yehyun [3 ]
Cho, Byoung Chul [1 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Dept Internal Med, Inst Gastroenterol, Seoul, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 104卷
关键词：
D O I：
10.1016/j.ejca.2018.09.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：104 / 107
页数：4
相关论文
共 50 条
  • [11] Immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of intrahepatic cholangiocarcinoma
    Huang, Wenpeng
    Zhang, Yongbai
    Liu, Yongshun
    Sun, Zhaonan
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2025, 117 (03) : 168 - 168
  • [12] Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
    Kim, In Young
    Eun, Yeonghee
    Kim, Hyungjin
    Ahn, Joong Kyong
    Park, Eun-Jung
    Jeon, Chan Hong
    Kim, Jinseok
    Cha, Hoon-Suk
    Koh, Eun-Mi
    Lee, Jaejoon
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [13] Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients
    Yun, Jenny S. W.
    Chan, On Bon
    Goh, Michelle
    McCormack, Christopher J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 (01) : 131 - 137
  • [14] Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
    Deligiorgi, Maria V.
    Siasos, Gerasimos
    Vergadis, Chrysovalantis
    Trafalis, Dimitrios T.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 83
  • [15] Clinical characteristics and microbiome analysis in patients with anti-programmed cell death protein 1 related colitis
    谭蓓
    China Medical Abstracts(Internal Medicine), 2021, 38 (01) : 50 - 50
  • [16] Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event
    Deligiorgi, Maria V.
    Trafalis, Dimitrios T.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 89
  • [17] Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in "anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes
    Sakai, Gota
    Saito, Daigo
    Nakajima, Ritsuko
    Hatano, Masako
    Noguchi, Yuichi
    Kurihara, Susumu
    Katayama, Shigehiro
    Inoue, Ikuo
    Noda, Mitsuhiko
    Shimada, Akira
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (02) : 448 - 449
  • [18] Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
    Le Burel, Sebastien
    Champiat, Stephane
    Mateus, Christine
    Marabelle, Aurelien
    Michot, Jean-Marie
    Robert, Caroline
    Belkhir, Rakiba
    Soria, Jean-Charles
    Laghouati, Salim
    Voisin, Anne-Laure
    Fain, Olivier
    Mekinian, Arsene
    Coutte, Laetitia
    Szwebel, Tali-Anne
    Dunogeant, Laetitia
    Lioger, Bertrand
    Luxembourger, Cecile
    Mariette, Xavier
    Lambotte, Olivier
    EUROPEAN JOURNAL OF CANCER, 2017, 82 : 34 - 44
  • [19] Lymphocyte Immune Response and T Cell Differentiation in Fontan Patients with protein-losing enteropathy
    Moosmann, Julia
    Toka, Okan
    Lukassen, Soeren
    Ekici, Arif B.
    Mackensen, Andreas
    Voelkl, Simon
    Dittrich, Sven
    THORACIC AND CARDIOVASCULAR SURGEON, 2021, 69 : E10 - E20
  • [20] Immune-Related Gastrointestinal Adverse Events Associated With Anti-programmed Cell Death Antibodies: A Meta-Analysis
    Chris-Olaiya, Abimbola
    Allen, Steven
    Nambudiri, Vinod
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S82 - S83
12345